ArticleScientific reports2026
The relationship between abdominal obesity indices and the risk of metabolic dysfunction-associated fatty liver disease: a prospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Abdominal obesity is a crucial risk factor for the onset of metabolic dysfunction-associated fatty liver disease (MAFLD). Chinese visceral adiposity index (CVAI), body roundness index (BRI), lipid accumulation product (LAP), and waist-to-hip ratio (WHR) are established indices of abdominal obesity. This study investigates the relations between these abdominal obesity indices and MAFLD onset. A total of 10,703 rural residents were included in this cohort study. Kaplan-Meier graphs, Cox regression modeling, restricted cubic spline (RCS) scores, Subgroup analyses and sensitivity analysis were used to conduct the study. During the median follow-up period of 5.79 years, 596 participants (5.57%) developed MAFLD. As the quartiles of the abdominal obesity indices increased, the incidence of MAFLD exhibited an increasing pattern. CVAI had the strongest association with MAFLD risk both before and after adjusting for confounders(P < 0.05). The associations between the indices and MAFLD risk were largely consistent across most subgroups, and the findings remained robust in sensitivity analyses. The RCS curves displayed linear correlations of CVAI with MAFLD risk (p for non-linear = 0.146) . CVAI, LAP, BRI, and WHR are all significantly and positively correlated with the risk of MAFLD. Among the female population, CVAI exhibited the strongest correlation with MAFLD risk. CVAI could serve as the preferred indicator for developing future risk prediction models for MAFLD in women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.